Skip to content
Moojaz — موجز
Search
Menu
HomeRegionsMaghrebAfricaMiddle EastEuropeAsiaAmericasWorldSectionsPoliticsEconomySecurityHealthScienceTechnologyAIEnvironmentCultureSportsSearch
Germany
File

Bayer: financial results and outlook

This dossier follows Bayer’s results and guidance, distinguishing actual performance from targets.

Last updated : 1 key moments
Bayer logo.
Logo used to identify the company. Bayer AG / Wikimedia Commons, public domain; PNG rendering. — Bayer AG / Wikimedia Commons — domaine public (PD-textlogo), version 2018 ; rendu PNG. Usage d’identification.

Where things stand

Bayer raised its 2026 outlook for EBITDA before special items on 3 November to €9.8–10.3 billion on a currency-adjusted basis, from €9.6–10.1 billion.

Confirmed

Bayer raises guidance despite quarterly net loss

Bayer raised its 2026 outlook for EBITDA before special items on 3 November to €9.8–10.3 billion on a currency-adjusted basis, from €9.6–10.1 billion.

Bayer logo.
Logo used to identify the company. Bayer AG / Wikimedia Commons, public domain; PNG rendering. — Bayer AG / Wikimedia Commons — domaine public (PD-textlogo), version 2018 ; rendu PNG. Usage d’identification.

The German group reported quarterly sales of €10.053 billion, up 4.1% as reported. EBITDA before special items rose 6.9% to €1.615 billion.

The operational improvement did not eliminate a €672 million net loss. Pharmaceuticals supported the guidance increase: the division now targets an annual adjusted EBITDA margin of 25–27%. These ranges remain company forecasts.

Sources 3